Evolution of payment models for cell and gene therapies in Italy

By Joanna Fernandes, Associate Consultant Email: jfernandes@partners4access.com Cell and gene therapies (CGTs) are considered one-time transformative treatments, positioned as having life-long benefits. These new therapies are challenging the traditional business model, with health technology assessment (HTA) and reimbursement processes having been established around chronic therapies. This has led to one of the biggest hurdles currently…

P4A sponsors World Orphan Drug Congress Europe 2019

Leading specialist market access consultancy Partners4Access has announced their gold sponsorship of the biotech industry conference World Orphan Drug Congress (WODC) Europe. The event will take place at Hotel Sofia, Barcelona between November 13-14, 2019. P4A’s Sophie Schmitz, managing partner; Akshay Kumar, partner; Aparna Krishnan, director and Nicola Allen, associate director will be attending the…

Orphan Drugs in Colombia: Practical Limitations to Access

By Ciaran Cassidy, Analyst Email: ccassidy@partners4access.com Colombia, like much of Latin America, is receiving attention from the pharmaceutical industry as an emerging market (1). Through the introduction of a universal healthcare system, it seems to provide an attractive opportunity for manufacturers. In this article we will review the Colombian healthcare system from an orphan drugs…

Scaling the healthcare wall: is Mexico an attractive market for high cost drug makers?

By Jack Rawson, Analyst Email: jrawson@partners4access.com At first glance Mexico presents a significant opportunity for drug manufacturers, with a large population of over 126 million, a developing economy and universal access to reimbursed healthcare. The aging population is also placing an increased need for healthcare services and statistics on the demand for drugs are favourable.…

Germany’s first outcomes deal for CAR-T-cell therapy

By Ciaran Cassidy, Analyst Email: ccassidy@partners4access.com Novartis recently announced an innovative reimbursement scheme with the GWQ –  (a body representing a small number of insurance funds in Germany) –  for its CAR-T cell therapy, Kymriah (tisagenlecleucel). Since September 2018, Kymriah has been used to treat patients up to the age of 25 with refractory and…

Future-proofing 2019 plans: P4A’s 6 Orphan Drug, Cell & Gene Therapy trends to watch out for

2019 is expected to a strong year for the orphan drug industry with an expected 10% surge in sales growth. Contributing to this growth will be new treatment launches particularly from cell and gene therapies. As these novel therapies are geared towards commercialization, the industry is witnessing a change in approach by manufacturers, regulators and…